BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25164760)

  • 21. Synthesis and biological evaluation of novel tamoxifen analogues.
    Christodoulou MS; Fokialakis N; Passarella D; García-Argáez AN; Gia OM; Pongratz I; Dalla Via L; Haroutounian SA
    Bioorg Med Chem; 2013 Jul; 21(14):4120-31. PubMed ID: 23735829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel silver iodide metalo-drug: experimental and computational modelling assessment of its interaction with intracellular DNA, lipoxygenase and glutathione.
    Banti CN; Kyros L; Geromichalos GD; Kourkoumelis N; Kubicki M; Hadjikakou SK
    Eur J Med Chem; 2014 Apr; 77():388-99. PubMed ID: 24681027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, Biological Investigation and Docking Study of Novel Chromen Derivatives as Anti-Cancer Agents.
    Dube PN; Sakle NS; Dhawale SA; More SA; Mokale SN
    Anticancer Agents Med Chem; 2019; 19(9):1150-1160. PubMed ID: 30848213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.
    Carr M; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
    J Enzyme Inhib Med Chem; 2016; 31(sup3):117-130. PubMed ID: 27476825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and antibreast cancer MCF-7 cells biological evaluation of heterocyclic analogs of resveratrol.
    Du C; Dong MH; Ren YJ; Jin L; Xu C
    J Asian Nat Prod Res; 2017 Sep; 19(9):890-902. PubMed ID: 27809606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
    Namba R; Young LJ; Maglione JE; McGoldrick ET; Liu S; Wurz GT; DeGregorio MW; Borowsky AD; MacLeod CL; Cardiff RD; Gregg JP
    Breast Cancer Res; 2005; 7(6):R881-9. PubMed ID: 16280035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bis-arylidene oxindoles as anti-breast-cancer agents acting via the estrogen receptor.
    Pal A; Ganguly A; Ghosh A; Yousuf M; Rathore B; Banerjee R; Adhikari S
    ChemMedChem; 2014 Apr; 9(4):727-32. PubMed ID: 24482362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticancer SAR models for MCF-7 and MDA-MB-231 breast cell lines.
    Qamar S; Carrasquer CA; Cunningham SL; Cunningham AR
    Anticancer Res; 2011 Oct; 31(10):3247-52. PubMed ID: 21965732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MTDH mediates estrogen-independent growth and tamoxifen resistance by down-regulating PTEN in MCF-7 breast cancer cells.
    Xu C; Kong X; Wang H; Zhang N; Kong X; Ding X; Li X; Yang Q
    Cell Physiol Biochem; 2014; 33(5):1557-67. PubMed ID: 24854844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microwave-assisted synthesis of sec/tert-butyl 2-arylbenzimidazoles and their unexpected antiproliferative activity towards ER negative breast cancer cells.
    Abdul Rahim AS; Salhimi SM; Arumugam N; Pin LC; Yee NS; Muttiah NN; Keat WB; Abd Hamid S; Osman H; Mat Ib
    J Enzyme Inhib Med Chem; 2013 Dec; 28(6):1255-60. PubMed ID: 23061895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel SERMs with a ferrocenyl entity based on the oxabicyclo[2.2.1]heptene scaffold and evaluation of their antiproliferative effects in breast cancer cells.
    Zheng Y; Wang C; Li C; Qiao J; Zhang F; Huang M; Ren W; Dong C; Huang J; Zhou HB
    Org Biomol Chem; 2012 Dec; 10(48):9689-99. PubMed ID: 23149805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis of 1H-1,2,3-Triazole-Linked Quinoline-Isatin Molecular Hybrids as Anti-Breast Cancer and Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Agents.
    Awolade P; Cele N; Ebenezer O; Kerru N; Gummidi L; Gu L; Palma G; Kaur M; Singh P
    Anticancer Agents Med Chem; 2021; 21(10):1228-1239. PubMed ID: 32990543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, in vitro cytotoxicity and apoptosis inducing study of 2-aryl-3-nitro-2H-chromene derivatives as potent anti-breast cancer agents.
    Rahmani-Nezhad S; Safavi M; Pordeli M; Ardestani SK; Khosravani L; Pourshojaei Y; Mahdavi M; Emami S; Foroumadi A; Shafiee A
    Eur J Med Chem; 2014 Oct; 86():562-9. PubMed ID: 25216378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
    Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
    Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and In Vitro Evaluation of Tetrahydroquinoline Derivatives as Antiproliferative Compounds of Breast Cancer via Targeting the GPER.
    Zacarías-Lara OJ; Méndez-Luna D; Martínez-Ruíz G; García-Sanchéz JR; Fragoso-Vázquez MJ; Bello M; Becerra-Martínez E; García-Vázquez JB; Correa-Basurto J
    Anticancer Agents Med Chem; 2019; 19(6):760-771. PubMed ID: 30451119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
    Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
    Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
    Li X; Wu C; Lin X; Cai X; Liu L; Luo G; You Q; Xiang H
    Eur J Med Chem; 2019 Jan; 161():445-455. PubMed ID: 30384047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator.
    Shoda T; Okuhira K; Kato M; Demizu Y; Inoue H; Naito M; Kurihara M
    Bioorg Med Chem Lett; 2014 Jan; 24(1):87-9. PubMed ID: 24332630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
    O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.